Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies

M. R. Matrana, C. Duran, A. Shetty, L. Xiao, B. J. Atkinson, P. Corn, L. C. Pagliaro, R. E. Millikan, C. Charnsangave, E. Jonasch, N. M. Tannir

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Aim The multi-tyrosine kinase inhibitor pazopanib prolongs progression-free survival (PFS) versus placebo in treatment-naive and cytokine-refractory metastatic clear-cell renal cell carcinoma (ccRCC). Outcomes and safety data with pazopanib after targeted therapy (TT) are limited. Methods We retrospectively evaluated records of consecutive patients with metastatic ccRCC who had progressive disease (PD) after TT and received pazopanib from November 2009 through November 2011. Tumour response was assessed by a blinded radiologist using Response Evaluation Criteria In Solid Tumours (RECIST). PFS and overall survival (OS) were estimated by Kaplan-Meier methods. Results Ninety-three patients were identified. Median number of prior TTs was 2 (range, 1-5). There were 68 events (PD or death). Among 85 evaluable patients, 13 (15%) had a partial response. Median PFS was 6.5 months (95% CI: 4.5-9.7); median OS was 18.1 months (95% CI: 10.26-NA). Common adverse events (AEs) included fatigue (44%), elevated transaminases (35%), diarrhoea (30%), hypothyroidism (18%), nausea/vomiting (17%), anorexia (14%) and hypertension exacerbation (14%); 91% of AEs were grade 1/2. Eleven patients (12%) discontinued therapy due to AEs. There were no treatment-related deaths. Concluding statement Pazopanib demonstrated efficacy in patients with metastatic ccRCC after PD with other TTs. Toxicity overall was mild/moderate and manageable.

Original languageEnglish (US)
Pages (from-to)3169-3175
Number of pages7
JournalEuropean Journal of Cancer
Volume49
Issue number15
DOIs
StatePublished - Oct 2013

Keywords

  • Angiogenesis
  • Mammalian target of rapamycin
  • Metastatic renal cell carcinoma
  • Pazopanib
  • Targeted therapy
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies'. Together they form a unique fingerprint.

  • Cite this

    Matrana, M. R., Duran, C., Shetty, A., Xiao, L., Atkinson, B. J., Corn, P., Pagliaro, L. C., Millikan, R. E., Charnsangave, C., Jonasch, E., & Tannir, N. M. (2013). Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. European Journal of Cancer, 49(15), 3169-3175. https://doi.org/10.1016/j.ejca.2013.06.003